Wells Fargo notes Abbott (ABT) and DexCom (DXCM) revealed that, on December 20, they had settled and entered into a cross-licensing agreement to resolve all outstanding patent litigation in the United States and Europe for 10 years. Under the agreement, the two companies granted a royalty-free, non-exclusive, fully paid-up worldwide license to certain patents and patent applications related to analytical sensing, including all patents asserted in the litigation. The company had expected the parties to settle eventually, so the announcement is not a complete surprise.
Published first TheFly – the ultimate source for real-time market-breaking financial news. Try Now >>
See Insiders' Hot Stocks on TipRanks >>
Read more on DXCM: